Third-Generation EGFR Inhibitors’ Safety Profiles Under Scrutiny At ASCO

In stark contrast with the first generation of EGFR inhibitors, Clovis’ CO-1386 has rash rates that are on par with placebo. But the drug must contend with high rates of excess blood sugar as well as QTc prolongation. AstraZeneca’s AZD9291 has its own safety issues, but coming efficacy results should carry the class.